{{ infobox .infobox-gene
| gene = PABPN1 [1]
| name = Poly(A) Binding Protein Nuclear 1
| chromosome = 14q11.2
| ncbi_gene_id = 9063
| ensembl = ENSG00000122591
| omim = 164171
| uniprot = Q86U42
| diseases = Oculopharyngeal Muscular Dystrophy
}}
PABPN1 (Poly(A) Binding Protein Nuclear 1) is a nuclear poly(A)-binding protein essential for mRNA processing and stability. While primarily studied in the context of oculopharyngeal muscular dystrophy (OPMD), emerging research suggests broader implications for RNA metabolism in neurodegenerative diseases. This gene encodes a protein that plays critical roles in polyadenylation, mRNA export, and translation regulation—processes increasingly recognized as dysfunctional in conditions like Alzheimer's disease, Parkinson's disease, and ALS.
PABPN1 is a multifunctional RNA-binding protein that participates in several key steps of mRNA metabolism:
Polyadenylation: PABPN1 binds to poly(A) tails and cooperates with the poly(A) polymerase to regulate tail length. It interacts with the cleavage and polyadenylation specificity factor (CPSF) complex to ensure proper 3'-end processing of pre-mRNA [1].
mRNA Export: The protein facilitates mRNA export from the nucleus to the cytoplasm by interacting with export receptors. This function is crucial for delivering processed mRNAs to ribosomes for translation [2].
Translation Regulation: PABPN1 modulates translation efficiency through its interaction with translation initiation factors. It can either enhance or repress translation depending on the mRNA context and cellular state.
mRNA Stability: By protecting poly(A) tails from deadenylation, PABPN1 contributes to mRNA stability and half-life. This function is particularly important for long-lived mRNAs involved in cellular homeostasis.
PABPN1 contains several functional domains:
The protein exists in multiple isoforms generated by alternative splicing:
The PABPN1 gene is located on chromosome 14q11.2 and spans approximately 16kb. It consists of:
PABPN1 expression is regulated by:
PABPN1 interacts with:
PABPN1 mutations cause autosomal dominant OPMD, characterized by:
Core clinical features:
Onset and progression:
Pathogenesis: Expanded polyalanine tract (17-18 alanine residues normal; 12-17 expanded) leads to nuclear protein aggregates. The expanded PABPN1 forms intranuclear inclusions that disrupt RNA processing [3][4].
Mechanism: Toxic gain-of-function from protein aggregates rather than loss of function. The aggregates sequester normal PABPN1 and other RNA-binding proteins.
Genetics: Most common mutation is (GCN)₁₇ repeat expansion in exon 1
Epidemiology:
Diagnosis:
Management:
While PABPN1 is not a major cause of classical neurodegenerative diseases, several mechanisms suggest connections:
PABPN1 dysfunction could contribute to:
RNA metabolism defects are increasingly recognized as central to neurodegeneration:
Similar to other RNA-binding proteins (TDP-43, FUS), PABPN1 aggregates have been observed in some ALS cases:
Key connections:
PABPN1 is expressed in:
The polyalanine expansion in PABPN1 leads to:
PABPN1 aggregates may: